{"id":37008,"date":"2025-07-09T14:01:29","date_gmt":"2025-07-09T06:01:29","guid":{"rendered":"https:\/\/flcube.com\/?p=37008"},"modified":"2025-07-09T14:01:29","modified_gmt":"2025-07-09T06:01:29","slug":"nk-celltech-secures-14-million-in-series-a-financing-to-advance-nk-cell-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37008","title":{"rendered":"NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies"},"content":{"rendered":"\n<p>China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB 100 million (approximately USD 14 million), with Pudong Venture Capital leading the investment. The funds will be allocated to accelerate clinical trials for core products and expand new pipelines, aiming to expedite the clinical translation of natural killer (NK) cell therapies.<\/p>\n\n\n\n<p><strong>Financing Details and Strategic Focus<\/strong><br>The Series A+++ round is a significant milestone for NK CellTech, as it underscores investor confidence in the company&#8217;s cutting-edge approach to NK cell therapy development. Proceeds from the financing will be utilized strategically to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerate Clinical Trials<\/strong>: Drive forward the development of NK CellTech&#8217;s core therapeutic candidates.<\/li>\n\n\n\n<li><strong>Expand Development Pipelines<\/strong>: Foster innovation through advanced research and development initiatives.<\/li>\n<\/ul>\n\n\n\n<p><strong>NK CellTech\u2019s Proprietary Technologies<\/strong><br>At the heart of NK CellTech&#8217;s competitive edge lies its ABCED-NK industrial production platform, enabling:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Allogeneic, Off-the-Shelf Expansion<\/strong>: Scalable production of NK cells from peripheral blood, achieving remarkable trillion-level cell yields per donation.<\/li>\n\n\n\n<li><strong>Advanced Cryopreservation<\/strong>: Ensuring the viability and readiness of NK cells for therapeutic applications.<\/li>\n<\/ul>\n\n\n\n<p>In addition to its robust manufacturing capabilities, NK CellTech leverages:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NKR-NK Target Discovery Technology<\/strong>: Identifying novel targets to enhance NK cell functionality.<\/li>\n\n\n\n<li><strong>SynNK Synthetic Immunology Technology<\/strong>: Engineering NK cells with multifunctional, intelligent, and controllable properties to improve tumor targeting, adaptability to the microenvironment, and donor-recipient compatibility.<\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Progress and Strategic Vision<\/strong><br>With two NK cell therapy products approved for clinical trials by both the U.S. FDA and China&#8217;s CDE, NK CellTech is advancing its pipeline across multiple therapeutic areas:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology<\/strong>: Targeting various cancers with innovative NK cell-based therapies.<\/li>\n\n\n\n<li><strong>Autoimmune Diseases<\/strong>: Exploring NK cell applications to modulate immune responses.<\/li>\n\n\n\n<li><strong>Neurodegenerative Disorders<\/strong>: Investigating potential treatments for conditions like Alzheimer&#8217;s and Parkinson&#8217;s.<\/li>\n<\/ul>\n\n\n\n<p>The company\u2019s ongoing Phase I trials and investigator-initiated studies (IITs) highlight its commitment to translating groundbreaking science into clinical solutions, positioning NK CellTech as a leader in the rapidly evolving field of cell therapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37012,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[757],"class_list":["post-37008","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-nk-celltech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB 100 million (approximately USD 14 million), with Pudong Venture Capital leading the investment. The funds will be allocated to accelerate clinical trials for core products and expand new pipelines, aiming to expedite the clinical translation of natural killer (NK) cell therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37008\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies\" \/>\n<meta property=\"og:description\" content=\"China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB 100 million (approximately USD 14 million), with Pudong Venture Capital leading the investment. The funds will be allocated to accelerate clinical trials for core products and expand new pipelines, aiming to expedite the clinical translation of natural killer (NK) cell therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37008\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-09T06:01:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0907.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37008#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37008\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies\",\"datePublished\":\"2025-07-09T06:01:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37008\"},\"wordCount\":337,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37008#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0907.webp\",\"keywords\":[\"NK CellTech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37008#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37008\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37008\",\"name\":\"NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37008#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37008#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0907.webp\",\"datePublished\":\"2025-07-09T06:01:29+00:00\",\"description\":\"China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB 100 million (approximately USD 14 million), with Pudong Venture Capital leading the investment. The funds will be allocated to accelerate clinical trials for core products and expand new pipelines, aiming to expedite the clinical translation of natural killer (NK) cell therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37008#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37008\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37008#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0907.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0907.webp\",\"width\":1080,\"height\":608,\"caption\":\"NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37008#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies - Insight, China&#039;s Pharmaceutical Industry","description":"China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB 100 million (approximately USD 14 million), with Pudong Venture Capital leading the investment. The funds will be allocated to accelerate clinical trials for core products and expand new pipelines, aiming to expedite the clinical translation of natural killer (NK) cell therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37008","og_locale":"en_US","og_type":"article","og_title":"NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies","og_description":"China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB 100 million (approximately USD 14 million), with Pudong Venture Capital leading the investment. The funds will be allocated to accelerate clinical trials for core products and expand new pipelines, aiming to expedite the clinical translation of natural killer (NK) cell therapies.","og_url":"https:\/\/flcube.com\/?p=37008","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-09T06:01:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0907.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37008#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37008"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies","datePublished":"2025-07-09T06:01:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37008"},"wordCount":337,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37008#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0907.webp","keywords":["NK CellTech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37008#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37008","url":"https:\/\/flcube.com\/?p=37008","name":"NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37008#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37008#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0907.webp","datePublished":"2025-07-09T06:01:29+00:00","description":"China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB 100 million (approximately USD 14 million), with Pudong Venture Capital leading the investment. The funds will be allocated to accelerate clinical trials for core products and expand new pipelines, aiming to expedite the clinical translation of natural killer (NK) cell therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37008#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37008"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37008#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0907.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0907.webp","width":1080,"height":608,"caption":"NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37008#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0907.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37008"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37008\/revisions"}],"predecessor-version":[{"id":37013,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37008\/revisions\/37013"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37012"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}